Published in JAMA on December 11, 2013
Do physical activity and dietary smartphone applications incorporate evidence-based behaviour change techniques? BMC Public Health (2014) 1.53
Warning Symptoms Are Associated With Survival From Sudden Cardiac Arrest. Ann Intern Med (2016) 1.49
Use of mobile apps: a patient-centered approach. Acad Emerg Med (2015) 1.42
Finding a depression app: a review and content analysis of the depression app marketplace. JMIR Mhealth Uhealth (2015) 1.37
Unaddressed privacy risks in accredited health and wellness apps: a cross-sectional systematic assessment. BMC Med (2015) 1.26
Exploring the Far Side of Mobile Health: Information Security and Privacy of Mobile Health Apps on iOS and Android. JMIR Mhealth Uhealth (2015) 1.24
The evolution of mobile apps for asthma: an updated systematic assessment of content and tools. BMC Med (2015) 1.21
Usability of Commercially Available Mobile Applications for Diverse Patients. J Gen Intern Med (2016) 1.19
Implementation of mobile health tools. JAMA (2014) 1.18
A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors. PeerJ (2016) 1.09
Health literacy and the digital divide among older Americans. J Gen Intern Med (2014) 1.02
Functional impairment and Internet use among older adults: implications for meaningful use of patient portals. JAMA Intern Med (2014) 1.00
Use of smartphones and mobile devices in hospitalized patients: Untapped opportunities for inpatient engagement. J Hosp Med (2015) 0.99
"Big data" and the electronic health record. Yearb Med Inform (2014) 0.97
mHealth for Schizophrenia: Patient Engagement With a Mobile Phone Intervention Following Hospital Discharge. JMIR Ment Health (2016) 0.96
Implementation of mobile health tools. JAMA (2014) 0.96
A mobile cloud-based Parkinson's disease assessment system for home-based monitoring. JMIR Mhealth Uhealth (2015) 0.96
PoopMD, a Mobile Health Application, Accurately Identifies Infant Acholic Stools. PLoS One (2015) 0.93
Mitigating HIV health disparities: the promise of mobile health for a patient-initiated solution. Am J Public Health (2014) 0.91
iMedEd: the role of mobile health technologies in medical education. Acad Med (2014) 0.90
mActive: A Randomized Clinical Trial of an Automated mHealth Intervention for Physical Activity Promotion. J Am Heart Assoc (2015) 0.88
Using social media to engage adolescents and young adults with their health. Healthc (Amst) (2014) 0.88
Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol (2014) 0.87
Exploring critical factors influencing physicians' acceptance of mobile electronic medical records based on the dual-factor model: a validation in Taiwan. BMC Med Inform Decis Mak (2015) 0.85
Use of mobile health (mHealth) tools by primary care patients in the WWAMI region Practice and Research Network (WPRN). J Am Board Fam Med (2014) 0.85
A Randomized Controlled Trial of a Mobile Health Intervention to Promote Self-Management After Lung Transplantation. Am J Transplant (2016) 0.84
Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015. J Am Heart Assoc (2015) 0.84
Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System. Interact J Med Res (2016) 0.83
Patient engagement and the design of digital health. Acad Emerg Med (2015) 0.83
Social media and mobile applications in chronic disease prevention and management. Front Psychol (2015) 0.83
Attitudes and preferences on the use of mobile health technology and health games for self-management: interviews with older adults on anticoagulation therapy. JMIR Mhealth Uhealth (2014) 0.82
Successful Organizational Strategies to Sustain Use of A-CHESS: A Mobile Intervention for Individuals With Alcohol Use Disorders. J Med Internet Res (2015) 0.81
Mobile Tele-Mental Health: Increasing Applications and a Move to Hybrid Models of Care. Healthcare (Basel) (2014) 0.80
A feasibility pilot using a mobile personal health assistant (PHA) app to assist stroke patient and caregiver communication after hospital discharge. Mhealth (2016) 0.79
Exploring the need for interventions to manage weight and stress during interconception. J Behav Med (2016) 0.79
Digital Connectedness in the Framingham Heart Study. J Am Heart Assoc (2016) 0.78
Big Data in Healthcare - Defining the Digital Persona through User Contexts from the Micro to the Macro. Contribution of the IMIA Organizational and Social Issues WG. Yearb Med Inform (2014) 0.77
Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and Development. JMIR Res Protoc (2017) 0.76
The Assessment of the Readiness of Molecular Biomarker-Based Mobile Health Technologies for Healthcare Applications. Sci Rep (2015) 0.76
A Multimodal mHealth Intervention (FeatForward) to Improve Physical Activity Behavior in Patients with High Cardiometabolic Risk Factors: Rationale and Protocol for a Randomized Controlled Trial. JMIR Res Protoc (2016) 0.75
Implementation of mobile health tools--reply. JAMA (2014) 0.75
Remote Patient Monitoring via Non-Invasive Digital Technologies: A Systematic Review. Telemed J E Health (2016) 0.75
What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions. PLoS One (2017) 0.75
Leveraging cues from person-generated health data for peer matching in online communities. J Am Med Inform Assoc (2016) 0.75
Mobile health for stroke: a promising concept for research and practice. Mhealth (2017) 0.75
Promoting adherence to treatment for latent TB infection through mobile phone text messaging: study protocol for a pilot randomized controlled trial. Pilot Feasibility Stud (2017) 0.75
mHealth and Health Information Technology Tools for Diverse Patients with Diabetes. J Diabetes Res (2017) 0.75
Insurance coverage & Whither Thou Goest for health information in 2012. Medicare Medicaid Res Rev (2014) 0.75
Emerging and Disruptive Technologies. EJIFCC (2016) 0.75
Using Fitness Trackers in Clinical Research: What Nurse Practitioners Need to Know. J Nurse Pract (2017) 0.75
Patient-oriented health technologies: Patients' perspectives and use. J Mob Technol Med (2017) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
Human genetic variation and its contribution to complex traits. Nat Rev Genet (2009) 12.11
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol (2009) 9.59
Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med (2011) 6.90
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev (2009) 6.85
Prevalence of conventional risk factors in patients with coronary heart disease. JAMA (2003) 6.84
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response. Nature (2011) 6.25
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol (2003) 5.51
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet (2004) 5.31
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol (2009) 4.80
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA (2005) 4.23
Pathway analysis of seven common diseases assessed by genome-wide association. Genomics (2008) 4.11
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science (2003) 3.34
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol (2004) 2.97
Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med (2012) 2.91
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med (2008) 2.91
Arthritis medicines and cardiovascular events--"house of coxibs". JAMA (2004) 2.89
Accurate detection and genotyping of SNPs utilizing population sequencing data. Genome Res (2010) 2.84
Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J (2005) 2.80
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation (2004) 2.54
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
International differences in evolution of early discharge after acute myocardial infarction. Lancet (2004) 2.47
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med (2011) 2.43
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am J Hum Genet (2004) 2.36
Enrichment of sequencing targets from the human genome by solution hybridization. Genome Biol (2009) 2.32
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA (2005) 2.26
The importance of phase information for human genomics. Nat Rev Genet (2011) 2.25
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24
Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med (2010) 2.23
The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol (2010) 2.19
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol (2003) 2.17
Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov (2003) 2.06
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05
The genetics of health. Nat Genet (2006) 2.04
Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med (2006) 2.02
Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics (2005) 2.01
A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol (2010) 1.98
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA (2005) 1.94
Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest (2006) 1.94
Identification of four gene variants associated with myocardial infarction. Am J Hum Genet (2005) 1.89
Impact of direct-to-consumer genomic testing at long term follow-up. J Med Genet (2013) 1.86
A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations. Proc Natl Acad Sci U S A (2009) 1.84
Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J (2009) 1.80
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study. PLoS Genet (2010) 1.76
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol (2003) 1.75
Cardiology and emergency medicine: united we stand, divided we fall. Ann Emerg Med (2002) 1.72
Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation (2002) 1.70
Critical role of STAT3 in leptin's metabolic actions. Cell Metab (2006) 1.70
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol (2007) 1.66
Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet (2004) 1.65
Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2009) 1.64
Direct-to-consumer personalized genomic testing. Hum Mol Genet (2011) 1.61
Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation. J Med Genet (2013) 1.61
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. Am J Cardiol (2002) 1.60
Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol (2006) 1.60
Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med (2003) 1.59
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol (2007) 1.59
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation (2002) 1.58
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J (2004) 1.58
Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation (2003) 1.55
Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J (2005) 1.54
Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am Heart J (2006) 1.53
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol (2003) 1.52
Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv (2010) 1.51
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J (2009) 1.49
An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. Am J Hum Genet (2007) 1.48
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet (2002) 1.47
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47